Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Bristol-Myers Squibb Co (NYSE: BMY) closed at $45.85 in the last session, up 0.99% from day before closing price of $45.4. In other words, the price has increased by $0.99 from its previous closing price. On the day, 11.75 million shares were traded. BMY stock price reached its highest trading level at $45.895 during the session, while it also had its lowest trading level at $45.045.
Ratios:
We take a closer look at BMY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.40. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.92 whereas as Long-Term Debt/Eq ratio is at 2.64.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.Cantor Fitzgerald initiated its Neutral rating on April 22, 2025, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 02 ’25 when Short Bartie Wendy sold 378 shares for $44.23 per share. The transaction valued at 16,719 led to the insider holds 5,066 shares of the business.
Hickey Benjamin sold 97 shares of BMY for $3,702 on May 09 ’25. The President, RayzeBio Org. now owns 0 shares after completing the transaction at $38.01 per share. On Apr 25 ’25, another insider, Hirawat Samit, who serves as the EVP,Chief Med.Offr.,Drug Dev. of the company, bought 4,250 shares for $47.58 each. As a result, the insider paid 202,215 and bolstered with 83,513 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 93324918784 and an Enterprise Value of 130764734464. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.50, and their Forward P/E ratio for the next fiscal year is 7.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.96 while its Price-to-Book (P/B) ratio in mrq is 5.35. Its current Enterprise Value per Revenue stands at 2.741 whereas that against EBITDA is 6.841.
Stock Price History:
The Beta on a monthly basis for BMY is 0.35, which has changed by -0.013978481 over the last 52 weeks, in comparison to a change of 0.21149921 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $42.96. The 50-Day Moving Average of the stock is -3.36%, while the 200-Day Moving Average is calculated to be -14.37%.
Shares Statistics:
According to the various share statistics, BMY traded on average about 14.43M shares per day over the past 3-months and 15220670 shares per day over the past 10 days. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 81.30% stake in the company. Shares short for BMY as of 1752537600 were 38384745 with a Short Ratio of 2.66, compared to 1749772800 on 33614196. Therefore, it implies a Short% of Shares Outstanding of 38384745 and a Short% of Float of 1.8900000000000001.
Dividends & Splits
The forward annual dividend rate for BMY is 2.46, which was 2.46 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.05418502The stock’s 5-year Average Dividend Yield is 3.67.
